US health advisors are poised to decide Thursday on whether to recommend the drug, Truvada, as the first preventive pill against AIDS instead of just a treatment for infected people.
Landmark study results published in 2010 showed that the drug, made by California-based Gilead Sciences, helped ward off HIV in gay men who engage in risky sex behaviors by 44 to nearly 73 percent.
But critics note that the pill is costly — up to $14,000 per year — and some warn that the clinical trial did not represent real-world circumstances and could lead to a spike in unprotected sex and a new surge in AIDS cases.
The Antiviral Drugs Advisory Committee is expected to issue a decision later Thursday. The Food and Drug Administration does not have to follow its advice, though it often does.
Truvada is currently available as a treatment for people with HIV in combination with other anti-retroviral drugs and was FDA approved in 2004.
Drug maker Gilead Sciences Inc. of California has filed a supplemental new drug application to market it for prevention purposes.
The data being mulled comes mainly from the iPrEx HIV Prevention Study, the research was carried out from July 2007 to December 2009 in six countries — Brazil, Ecuador, Peru, South Africa, Thailand and the United States.
The study was conducted among 2,499 men, including 29 transgendered women, between the ages of 18 and 67 who were sexually active with other men but were not infected with the virus that causes AIDS.
Participants were selected at random to take a daily dose of Truvada — a combination of 200 milligrams of emtricitabine and 300 milligrams of tenofovir disoproxil fumarate — or a placebo.
Those in the study who took the drug regularly had almost 73 percent fewer infections. Across the entire study, including those who had not been as faithful in taking Truvada, there were 44 percent fewer infections than those who took a placebo.
The method of taking a drug ahead of potential exposure to HIV is called pre-exposure prophylaxis (PrEP).
After the study’s publication in the New England Journal of Medicine, some experts hailed the results as game-changing and the first demonstration that an already-approved oral drug could decrease the likelihood of HIV infections.
However, others have warned of the risks of depending on people — particularly those who may be already engaged in careless behaviors — to take a daily pill.
“There could be an increased risk to men as they may falsely believe they are 100 percent protected and stop using condoms. A reduction in condom use will mean increased risk of transmission and the spread of a drug-resistant virus,” said a statement from the AIDS Healthcare Foundation.
“The 44 percent who received a benefit from Truvada in the iPrex Study were intensively counseled monthly and tested frequently for sexual infections — this is not likely to occur in the real world.”
Gay men account for more than half of the 56,000 new cases yearly of human immunodeficiency virus in the United States, according to the Centers for Disease Control and Prevention.
A cost-benefit analysis by experts at Stanford University last month suggested the pill would make financial sense among gay men with five or more sex partners per year, but could be prohibitively expensive if promoted for all gay men.
[Bottles of antiretroviral drug Truvada. AFP Photo/Justin Sullivan]
Here is how the 99% can force the 1% to defeat COVID-19
The government's response to the pandemic has further enriched the wealthy, while everyday people, especially Black and Brown workers, face sickness, death, and destitution. Government handouts to the rich are unsurprising, since they repeat the century-old pattern of "rescue packages", but another pattern is more perplexing: why have business leaders not stepped up to demand a robust public health response, which would ultimately be in their own self-interest? The titans of industry have mostly stood by in the face of Trump's criminal negligence, which has devastated much of the 99% but also endangers the wealthy.
Trump Organization planning ‘high-end’ retirement community — with 225 properties — on foreign soil: report
The Trump Organization is planning a massive real estate development, according to a new report by Martyn McLaughlin in The Scotsman.
"In what would be one of the most ambitious and expensive foreign projects undertaken by Donald Trump’s family business since he assumed the presidency, his company has commissioned a detailed masterplan to develop as many as 225 properties, as well as leisure facilities and shops, on an expanse of rolling farmland adjacent to Turnberry’s lauded Ailsa course, a four-time host of golf’s Open Championship," the Scottish newspaper reported.
WATCH: Video shows how Trump makes his caddie hang on to the back of the golf cart
Despite the ongoing coronavirus pandemic and economic catastrophe, the leader of the free world spent the weekend golfing at his private, for-profit golf course in Virginia.
For the second day in a row, Donald Trump's presidential motorcade traveled to Trump National Golf Club in Sterling, Virginia.
"Today marks the president’s 86th day trip to Sterling," reported HuffPost correspondent S.V. Dáte, who was the White House pool reporter for print covering the day's events.